Synaffix, a Netherlands-based biotechnology company, wins the Best ADC Platform Technology at the 7th Annual World ADC Awards.
The 7th Annual World ADC awards ceremony was held on September 17, 2020. The ceremony signified innovation, dedication, and dedication laid out by the best individuals, teams, and companies in the respective industry.
Synaffix is a Netherlands-based biotechnology company that focuses specifically on the continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology platform.
The prohibitive technology of Synaffix was created to empower the treatment of a vast collection of cancer types. Furthermore, it intends to upgrade the viability altogether while improving the security and decency of these focused on cancer therapeutics.
Their vision is to become the preferred partner in the development of these complex biological therapeutics and realize their ambition—connect to cure.
Synaffix has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs), which are used primarily to treat cancer.
ADCs are a class of biopharmaceutical drugs created as a ‘targeted therapy’ for treating cancer.
The ADCs use strong little molecule payloads, like those utilized for chemotherapy. However, they are intended to target just the cancer cells and extra typical, sound tissues.
ADCs combine the focusing on capacities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. Moreover, they can be intended to separate among healthy and diseased tissue.
The world ADC awards 2020
The World ADC announced winners for its 7th annual World ADC Awards on September 17, 2020.
Synaffix was named the Best ADC platform technology at the awards. At the same time, Legochem Bio came runner up in the same category. The prize was won by Zymeworks in the 2019 awards ceremony, while Legochem Bio were runner ups that time as well.
— Synaffix (@Synaffix) September 16, 2020
Here are the nominees for the award:
In contrast to the awards’ finalists, the program director of the World ADC San Diego, Elayda Hearne, stated that the finalists reflect this year concerning the ADC space with “novel innovations” and “world-class research.” Furthermore, Elayda expressed her delight over the demonstration of dedication, innovation, and leadership regarding their existence in the area of Oncology Therapeutics.
Moreover, the senior vice president of Research and Development at the ModMab Therapeutics, Jagath Reddy Junutula, explained why the World ADC Summit is his favorite scientific conference. It is because it unifies all ‘ADC players’ on to a single platform. In addition to that, he explained how these awards enlighten the ADC field.
Image courtesy of crystal light/Shutterstock